Chronotropic incompetence does not contribute to submaximal exercise limitation in patients with chronic heart

Klaus K Witte1, Andrew L Clark

  • 1Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, UK. klauswitte@hotmail.com

Insights

Chronotropic incompetence is unlikely to cause exercise intolerance in chronic heart failure (CHF) patients. Patients exhibit a lower workload/heart rate ratio, suggesting heart rate limitations are a consequence, not a cause, of their reduced exercise capacity.

Area of Science:

  • Cardiology
  • Exercise Physiology

Background:

  • Chronic heart failure (CHF) patients often experience breathlessness and fatigue during exercise.
  • A traditional hypothesis suggests 'chronotropic incompetence' (limited heart rate increase) contributes to exercise intolerance in CHF.

Purpose of the Study:

  • To investigate the relationship between heart rate and workload in patients with CHF during exercise.
  • To determine if chronotropic incompetence is a cause or consequence of exercise intolerance in CHF.

Main Methods:

  • Calculated workload/heart rate ratios during peak and submaximal (15%, 25%, 50% of peak) exercise tests.
  • Compared these ratios between CHF patients and control subjects.
  • Assessed the relationship between heart rate and workload using correlation analysis.

Main Results:

  • CHF patients had a lower workload/heart rate ratio during peak exercise compared to controls.
  • During submaximal exercise, CHF patients had lower absolute workload and oxygen consumption but similar heart rates to controls, resulting in a lower workload/heart rate ratio.
  • A significant relationship between heart rate and workload was found in controls (r=0.85), but not in CHF patients (r=0.003) during steady-state exercise.

Conclusions:

  • Heart rate limitation is likely a consequence, rather than the primary cause, of exercise intolerance in CHF.
  • CHF patients demonstrate a blunted heart rate response relative to workload during exercise, indicating altered cardiovascular regulation.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...